Trastuzumab in HER2-positive metastatic breast cancer that has progressed on anthracyclines, taxanes and trastuzumab therapy. The combination showed significantly improved progression-free survival and had  <a href=”http://www.selleckbio.com/eta-receptor.html”>ETA-receptor review</a> a Hnlichen effect c Ty compared with lapatinib alone professional. One death was Kardiotoxizit t connected in the combination arm. An asymptomatic decrease in left ventricular Ren ejection fraction was also h More frequently in the combination arm. In summary, the data show that combined targeting HER 2 showed better clinical results compared with lapatinib alone in metastatic, with a profit Hnlichen side effect. Ongoing studies with lapatinib and trastuzumab in a Phase III study comparing paclitaxel and trastuzumab with lapatinib or placebo in metastatic breast cancer, HER-2 positive and a Phase I study combining lapatinib, trastuzumab, carboplatin and paclitaxel.<br> Bevacizumab is a monoclonal antibody Body is directed  <a href=”http://www.selleckbio.com/flt.html”>Flt pathway</a> against VEGF, and has shown promising activity t in combination with trastuzumab in pr Clinical models. However, the Kardiotoxizit t this combination has not been established professional. HER-2 inhibition by lapatinib may be a less cardiotoxic. A phase II single-arm is to evaluate the combination of lapatinib and bevacizumab in 50 patients with HER 2-positive metastatic breast cancer. Preferences INDICATIVE data show a progression-free survival time of 12 weeks, 62% in 16 of 21 patients evaluated, and the combination is well tolerated Possible.<br> An evaluation of Phase II of lapatinib in combination with the struggle against the angiogenic tyrosine kinase is pazopanib lapatinib alone against the tide in patients who do not have again U prior treatment for progressive disease. Preferences INDICATIVE reports show 44% of the response rate of 30% for the combination arm compared with 73% compared to 43% reduction of the target L Emissions by 12 weeks. Biomarkers of response to lapatinib Seems similar to treatment with trastuzumab, their 2-overexpression on the most reliable Ssigste pr Diktiver marker of response to lapatinib in breast cancer to be. HER-2 in the Bev Lkerung positive breast cancer biomarkers is ben CONFIRMS, kidney to define which patients are likely to benefit from continued treatment with lapatinib. Biomarkers of response to lapatinib monotherapy were investigated in the Phase I study EGF10004.<br> Although the numbers were limited, clinical responses were obtained with a Hten expression of HER-2 pretreatment, p assigned to HER-2, ERK1 / 2, ERK1 / 2, insulin Like growth factor receptor 1, p70 S6 kinase, and Table Transforming growth has four Phase II studies of lapatinib combined with complete III for advanced / metastatic breast cancer study ID Bev Lkerung the n-phase plan EGF102580a result 1500 ppm OD x 14 days  II 296 PFS: HR 0.77 OS: HR Study aneoadjuvant 0.75. Abbreviations: OD, once a day, RR, response rate, TTP, time to progression, OS overall survival, progression-free survival survival, progression-free, T, trastuzumab, EABC, cancer, locally advanced breast cancer, MBC, metastatic breast cancer, IBC, infl ammatory breast cancer, PR, some new